Mark D. Rothmann - Concepedia

Author

Mark D. Rothmann

United States Food and Drug Administration ORCID

Also Known As

Mark D Rothmann, Mark D. Rothmann, Mark Rothmann, Mark.D. Rothmann

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research Cancer Research And Biostatistics University of Washington

About

Mark D. Rothmann is an author at United States Food and Drug Administration specializing in medicine, clinical trials, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	958
2	Health Sciences	3	3	479
3	Engineering	2	2	46
4	Business	1	1	12
5	Education	1	1	14

Mark D. Rothmann

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Martin H. Cohen, Grant Williams, John R. Johnson, PubMed	2002	469
Design and analysis of non‐inferiority mortality trials in oncology Mark D. Rothmann, Ning Li, Gang Chen, Statistics in Medicine	2002	241
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Mark D. Rothmann, Jogarao Gobburu, Gabriel J. Robbie, PubMed	2002	240
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma Thomas M. Herndon, Albert Deisseroth, Edvardas Kaminskas, Clinical Cancer Research Hematological MalignancyThrombosisTranslational MedicineMultiple Myeloma RefractoryU.s. Food	2013	240
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski, Clinical Cancer Research Lymphoid NeoplasiaTranslational MedicineHodgkin LymphomaU.s. FoodMedicine	2012	207
Issues in Using Progression-Free Survival When Evaluating Oncology Products Thomas R. Fleming, Mark D. Rothmann, Hong Lü Journal of Clinical Oncology Progression-free SurvivalOncology TrialsTumor MicroenvironmentMedicineCancer Management	2009	168
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis Albert Deisseroth, Edvardas Kaminskas, Joseph A. Grillo, Clinical Cancer Research Hematological MalignancyAntifibrotic TherapyOncologyU.s. FoodMetronomic Therapy	2012	143
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. John R. Johnson, Peter Bross, Martin H. Cohen, PubMed	2003	102
U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia Firoozeh Alvandi, Virginia E. Kwitkowski, Chia‐Wen Ko, The Oncologist PharmacotherapyPre-clinical PharmacologyMyeloid NeoplasiaHematological MalignancyTranslational Medicine	2013	96
U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens Ruthann M. Giusti, Kaushikkumar A. Shastri, Anne M. Pilaro, Clinical Cancer Research	2008	92

Page 1